Abstract
Background: In children and adolescents, growth hormone (GH) therapy requires a long-term commitment to daily subcutaneous injections. Improvements in device delivery methods have been made, including injection pens, autoinjector pens, and needle-free delivery devices. Because of the requirement for daily injections, patient acceptance of devices is important. Developments that improve patient acceptance will likely increase compliance with GH therapy. A novel electronic injection delivery device (e-device) that allows for physician programmed preset dosing, cartridge alarms, and injection monitoring is now available. A user trial, evaluating the performance and handling of this device among subjects, nurses, and physicians, is described.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
